Idorsia Ltd
🇨🇭XSWX.IDIASwitzerlandNot reported
PriceCHF 4.44+0.08 (+1.83%)
Latest anomalies
Negative 1 detected in the last 120 days
- High: 6
- Medium: 2
- Low: 0
Volume: a spike above the 20-day average
Asset turnover: a sudden spike above its trailing quarter average
Capital expenditure to revenue: a sudden spike above its trailing quarter average
Effective tax rate: a sudden drop below its trailing quarter average
Fixed asset turnover: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0363463438
- CUSIP
- Not reported
Company
- Employees
- Not reported
- Headquarters
- Germany
- Website
- Not reported
Market
- Shares outstanding
- 269.1M
- Market cap
- CHF 906.37M
Highlights
- Market cap
- CHF 906.37M
- EPS LTM
- -CHF 0.65
- P/E LTM
- -6.79calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 217.23M+69.92%up year on year
- Net income
- -CHF 133.26M-564.99%down year on year
- Gross margin
- 49.28%-42.47%down year on year
- Free cash flow
- -CHF 261.77M+37.9%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Idorsia Ltd is listed on SIX Swiss Exchange (Switzerland) under the ticker IDIA. Its market capitalisation is CHF 906.37M, from 269.1M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 2.80 and CHF 7.56, and the last close of CHF 4.44 sits 34% of the way up that range. The same company also trades as 19T on Frankfurt Stock Exchange, and as 19T on Stuttgart Stock Exchange.
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat immune-mediated disorders; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and optional license and/or research and development collaboration agreement with Neurocrine Biosciences, Inc, to to develop and commercialize ACT-709478, and/or to collaborate in a research program to discover, identify and develop novel calcium channel blocker compounds for follow-on compounds to ACT-709478. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.